Jorge Santos da Silva - Feb 27, 2024 Form 4 Insider Report for MoonLake Immunotherapeutics (MLTX)

Signature
/s/ Matthias Bodenstedt, Attorney-in-fact for Jorge Santos da Silva
Stock symbol
MLTX
Transactions as of
Feb 27, 2024
Transactions value $
-$6,803,044
Form type
4
Date filed
2/29/2024, 07:56 PM
Previous filing
Feb 23, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MLTX Class A ordinary shares, par value $0.0001 per share Sale -$3.45M -62.8K -2.02% $55.00 3.04M Feb 27, 2024 Direct F1
transaction MLTX Class A ordinary shares, par value $0.0001 per share Sale -$3.08M -56.1K -1.84% $55.00 2.99M Feb 28, 2024 Direct F1
transaction MLTX Class A ordinary shares, par value $0.0001 per share Sale -$265K -4.74K -0.16% $55.89 2.98M Feb 29, 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 17, 2023.
F2 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.50 to $57.55. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.